腌菜添加違禁品檢測(cè)試紙

廣州健侖生物科技有限公司

主營(yíng)品牌：美國(guó)US、美國(guó)Alfa、美國(guó)NovaBios、美國(guó)Cortez、國(guó)產(chǎn)創(chuàng)侖等等。

主要用途：篩查違禁品濫用殘留、麻醉類藥物殘留、興奮類藥物殘留等等。

獨(dú)立包裝：BZO-BAR-COC--THC -MET--OPI-OXY-MDMA-PCP- AMP-XTC-MTD 或聯(lián)檢

腌菜添加違禁品檢測(cè)試紙

The One Step Drug Screen Test Card is an immunoassay based on the principle of competitive binding. Drugs which may be present in the urine specimen compete against their respective drug conjugate for binding sites on their specific antibody.

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody.  Therefore, the colored line will not form in the test line region.

A drug-positive urine specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative urine specimen will generate a line in the test line region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

The test contains a membrane strip coated with drug-protein conjugates (purified bovine albumin) on the test line, a goat polyclonal antibody against gold-protein conjugate at the control line, and a dye pad which contains colloidal gold particles coated with mouse monoclonal antibody specific to Cocaine and Marijuana.

• For healthcare professionals including professionals at point of care sites.
• For in vitro diagnostic use only. Do not use after the expiration date.
• The test panel should remain in the sealed pouch until use.
• All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
• The used test card should be discarded according to federal, state and local regulations.
• OPI一步試驗(yàn)條是一種橫向流動(dòng)色譜免疫分析法，用于在2000 ng / mL的截留濃度下檢測(cè)尿液中的OPI制劑。
  該測(cè)定僅提供初步的分析測(cè)試結(jié)果。 必須使用更具體的替代化學(xué)方法才能獲得確認(rèn)的分析結(jié)果。 氣相色譜/質(zhì)譜（GC / MS）是優(yōu)選的確認(rèn)方法。 臨床考慮和專業(yè)判斷應(yīng)適用于任何濫用藥物的濫用測(cè)試結(jié)果，特別是當(dāng)使用初步的肯定結(jié)果時(shí)。

【檢驗(yàn)方法】

在進(jìn)行檢測(cè)前必須先完整閱讀使用說明書，使用前將本品和尿樣恢復(fù)至室溫（20℃～30℃）。

• 撕開鋁箔袋，取出試劑盒，應(yīng)在1小時(shí)內(nèi)盡快使用。
• 將試劑盒置于干凈平坦的臺(tái)面上，用塑料吸管垂直滴加3滴無空氣泡的尿樣（約100µL）于加樣孔（S）中。
• 等待紫紅色條帶的出現(xiàn)，3～5分鐘時(shí)直接觀察結(jié)果，10分鐘后判定無效。

【參考值（參考范圍）】

本品zui低檢出量指標(biāo)參照美國(guó)藥物濫用和精神健康服務(wù)管理局(SAMHSA)確定的陽性檢測(cè)臨界濃度的標(biāo)準(zhǔn)進(jìn)行制定。能檢測(cè)出尼古丁含量不低于300ng/mL的樣本。

【檢驗(yàn)結(jié)果的解釋】

陽性（+）：僅在控制區(qū)（C）出現(xiàn)一條紫紅色條帶，在檢測(cè)區(qū)（T）無紫紅色條帶出現(xiàn)。陽性結(jié)果表明尿液中的尼古丁濃度在閾值（300ng/mL）以上。

陰性（-）：出現(xiàn)兩條紫紅色條帶。一條位于檢測(cè)區(qū)（T），另一條位于控制區(qū)（C）。陰性結(jié)果表明尿液中的尼古丁濃度在閾值（300ng/mL）以下。

無效：控制區(qū)（C）未出現(xiàn)紫紅色條帶。表明操作不當(dāng)或試劑盒已失效。在此情況下，應(yīng)再次仔細(xì)閱讀說明書，并用新的試劑盒重新測(cè)試。如果問題仍然存在，應(yīng)立即停止使用此批號(hào)產(chǎn)品，并與當(dāng)?shù)毓?yīng)商。

注意：檢測(cè)區(qū)（T）紫紅色條帶可呈現(xiàn)顏色深淺的現(xiàn)象。但是，在規(guī)定的觀察時(shí)間內(nèi)，不論該色帶顏色深淺，即使只有非常弱的色帶也應(yīng)判定為陰性結(jié)果。

美國(guó)NOVABIOS多聯(lián)檢測(cè)杯簡(jiǎn)介：

美國(guó)NOVABIOS單卡產(chǎn)品簡(jiǎn)介：

傳統(tǒng)基于PCR的克隆方法或者通過構(gòu)建基因組文庫篩選等方法存在著克隆片段長(zhǎng)度的限制、易產(chǎn)生突變、步驟復(fù)雜、效率低下等缺點(diǎn)，并不適合大片段基因組的克隆。因此開發(fā)一種快速簡(jiǎn)單的方法來獲得大尺度的基因簇片段至關(guān)重要，這也是目前許多實(shí)驗(yàn)室的課題之一。
近日，中科院微生物所婁春波課題組與清華大學(xué)、特拉維夫大學(xué)合作開發(fā)了利用CRISPR-Cas9系統(tǒng)一步靶向克隆上百kb基因簇片段的方法。CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) /Cas (CRISPR-associated) 是近年出現(xiàn)的一種由RNA介導(dǎo)Cas核酸酶對(duì)靶向基因進(jìn)行特定DNA修飾的技術(shù)。它是細(xì)菌和古細(xì)菌為應(yīng)對(duì)細(xì)菌毒和質(zhì)粒的不斷攻擊而演化來的獲得性免疫防御機(jī)制。
該系統(tǒng)的工作原理是crRNA (CRISPR-derived RNA) 通過堿基配對(duì)與 tracrRNA (trans-activating RNA) 結(jié)合形成 tracrRNA/crRNA 復(fù)合物，此復(fù)合物引導(dǎo)核酸酶 Cas9 蛋白在與 crRNA 配對(duì)的序列靶位點(diǎn)處剪切雙鏈 DNA，從而實(shí)現(xiàn)對(duì)基因組DNA序列進(jìn)行編輯；而通過人工設(shè)計(jì)這兩種 RNA，可以改造形成具有引導(dǎo)作用的gRNA (guide RNA)，足以引導(dǎo) Cas9 對(duì) DNA 的定點(diǎn)切割。Cas9 能在任何 dsDNA 序列處帶來任何融合蛋白及RNA，這為生物體的研究和改造帶來巨大潛力。
基于CRISPR-Cas9系統(tǒng)的原理，研究人員利用RNA介導(dǎo)的CRISPR-Cas9核酸內(nèi)切酶精確的切割所需克隆的任意基因簇片段兩側(cè)，并通過Gibson組裝方法將切割下來的大片段與目標(biāo)載體進(jìn)行連接，達(dá)到一步克隆的目的。利用該方法成功克隆了不同尺度（50-150 kb）的大腸桿菌基因組片段，并在其他細(xì)菌（枯草芽孢桿菌、鏈霉菌）中成功克隆了芽孢、金霉素、杰多霉素等生物合成基因簇。
該技術(shù)的成功，將大大促進(jìn)功能基因組學(xué)的研究，以及其它需要進(jìn)行大片段克隆的研究。目前，該技術(shù)已于2015年9月1日在Nature Communications 雜志在線發(fā)表，文章*作者是清華大學(xué)博士生姜文君，微生物所趙學(xué)金博士做出了前期的重要貢獻(xiàn)，并PCR（聚合酶鏈?zhǔn)椒磻?yīng)）是分子生物學(xué)實(shí)驗(yàn)室細(xì)菌見技術(shù)，也是DNA測(cè)序的必須步驟。PCR技術(shù)自出現(xiàn)以來，就被廣泛用于生物學(xué)的各個(gè)研究領(lǐng)域，對(duì)生物學(xué)的發(fā)展起到了極大的推動(dòng)作用。然而，相比于其他分子技術(shù)，PCR技術(shù)出現(xiàn)以后發(fā)展緩慢，至今沒有大的改進(jìn)與創(chuàng)新，是細(xì)菌通量測(cè)序與規(guī)模化檢測(cè)的一個(gè)限制因素。

尿液試紙、唾液試紙、尼古丁檢測(cè)卡、煙堿檢測(cè)卡、違違禁品三聯(lián)檢測(cè)卡、違禁品五聯(lián)檢測(cè)卡、違禁品十聯(lián)檢測(cè)卡、藥篩試劑、違禁品濫用檢測(cè)試紙、違禁品快速檢測(cè)試劑盒

更多產(chǎn)品說明可通過下方的進(jìn)行了解

添加掃一掃二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【 市場(chǎng)部 】       楊永漢
【】 
【騰訊  】
【公司地址】 廣州市清華科技園健新基地番禺石樓鎮(zhèn)健啟路63號(hào)二期2幢101-103室

Traditional PCR-based cloning methods or the construction of genomic library screening methods have the limitations of cloning fragment length, easy to produce mutations, complex steps, low efficiency and other shortcomings, is not suitable for large fragment cloning of the genome. Therefore, it is of crucial importance to develop a fast and simple method to obtain large-scale gene cluster fragments, which is also one of the topics in many laboratories at present.
Recently, Lou Chunbo, a member of the Chinese Academy of Sciences Institute of Microbiology, collaborated with Tsinghua University and Aviv University to develop a method for the targeted cloning of hundreds of kb gene cluster fragments using the CRISPR-Cas9 system. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) / Cas (CRISPR-associated) is a technology that has been used to perform specific DNA modification of target genes by RNA-mediated Cas nuclease in recent years. It is an acquired immune defense mechanism that bacteria and archaebacteria evolve in response to the constant attack of bacterial viruses and plasmids.
The system works by crRNA (CRISPR-derived RNA) binding to tracrRNA (trans-activating RNA) by base pairing to form a tracrRNA / crRNA complex that directs the expression of the nuclease Cas9 protein at the sequence target site paired with the crRNA Double-stranded DNA cut in order to achieve the editing of the genomic DNA sequence; and by artificial design of these two RNA, you can transform the formation of a guide gRNA (guide RNA), enough to guide Cas9 site-directed DNA cleavage. Cas9 can bring in any fusion protein and RNA at any dsDNA sequence, which has great potential for the research and modification of organisms.
Based on the principle of the CRISPR-Cas9 system, the researchers used RNA-mediated CRISPR-Cas9 endonucleases to precisely cut both sides of any gene cluster fragment of the desired clone and ligated the cut large fragment to a target vector To connect, to achieve the purpose of one-step cloning. Using this method, we successfully cloned Escherichia coli genome fragments of different sizes (50-150 kb) and successfully cloned the biosynthetic genes of spore, chlortetracycline and gentamycin in other bacteria (Bacillus subtilis and Streptomyces) cluster.
The success of this technology will greatly facilitate functional genomics research and other studies that require large fragment cloning. At present, this technology was published online in Nature Communications magazine on September 1, 2015. The lead author of this article is Jiang Wenjun, a doctoral student at Tsinghua University, and Dr. Zhao Xuejin from the Institute of Microbiology made an important contribution in the previous period. PCR (Polymerase Chain Reaction) is a molecular biology laboratory see the technology of bacteria, but also a necessary step in DNA sequencing. Since its emergence, PCR technology has been widely used in various fields of biology and has greatly promoted the development of biology. However, compared with other molecular technologies, PCR technology has been slow to develop since the advent of PCR technology, and so far no major improvements and innovations have been identified as a limiting factor for bacterial flux sequencing and mass detection.